Choriogonadotropin Alfa (Ovidrel)
Overview
Choriogonadotropin alfa is a recombinant human chorionic gonadotropin produced in Chinese hamster ovary cells with identical amino acid sequence to endogenous hCG. The 237-amino acid heterodimeric glycoprotein binds the LH/hCG receptor on ovarian granulosa and theca cells to trigger final oocyte maturation and ovulation. It is used in assisted reproductive technology protocols to time oocyte retrieval and support luteal phase progesterone production.
Key Research Findings
FDA approval was granted in 2000 following controlled trials demonstrating comparable efficacy to urinary-derived hCG in triggering ovulation and supporting ART outcomes. Multicenter studies published in Fertility and Sterility confirmed equivalent pregnancy rates with improved dosing consistency due to recombinant production. The agent is now a standard component of ovulation induction and IVF protocols worldwide.
Subcutaneous injection
FDA Approved
Interested in Choriogonadotropin Alfa (Ovidrel)?
Find a verified provider experienced with Choriogonadotropin Alfa (Ovidrel) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Choriogonadotropin Alfa (Ovidrel) ProviderRelated Peptides
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory phase (flare effect) lasting 1-2 weeks, chronic leuprolide administration downregulates pituitary GnRH receptors, resulting in profound suppression of LH, FSH, and downstream sex steroids. This chemical castration effect is exploited in treating hormone-sensitive cancers, endometriosis, and precocious puberty.
Goserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other GnRH agonists, goserelin initially stimulates and then suppresses the HPG axis, reducing sex hormone production to castrate or postmenopausal levels. The implant formulation eliminates the need for repeated injections and ensures compliance.
Cetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose-dependent suppression of LH and FSH without the initial flare effect seen with GnRH agonists. Cetrorelix prevents premature LH surges during controlled ovarian stimulation in IVF, allowing precise timing of oocyte maturation and retrieval.
Ganirelix
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells. Ganirelix rapidly suppresses LH secretion within hours of administration, preventing premature ovulation during assisted reproductive technology (ART) cycles. Its mechanism provides immediate suppression without the flare phase associated with GnRH agonists.